browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
fd6cb54a-b135-4833-b9f0-0120185c75c3
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 13:49:28
Income (reported)
Expenses (reported)
$730,000
Expenses method
A
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

APOTEX CORP.

Generic pharmaceutical manufacturer

Contact
STEVE GIULI
Phone
+1 954-384-8007
Address
zip:33326, city:WESTON, state:FL, street:2400 N. COMMERCE PARKWAY
Client

APOTEX CORP.

State
FL
Country
US
Government-entity client
false
Effective date
2006-07-20
Issues lobbied + lobbyists (3)

MAN — Manufacturing

Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs and their ingredients; Federal policy relating to amending the Hatch-Waxman Act to provide incentives for manufacturing generic pharmaceuticals and their ingredients in the United States and allied nations. Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; and Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

TRD — Trade (domestic/foreign)

Federal policy relating to the review of the United States-Mexico-Canada trade agreement and the North American generic drug supply chain; and Federal policy relating to the United States-Mexico-Canada trade agreements rules of origin requirements for pharmaceuticals.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

CPT — Copyright/Patent/Trademark

HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; HR 3269/S. 2276, the Eliminating Thickets to Increase Competition (ETHIC) Act, provisions relating to capping the number of patents that can be asserted against biosimilar and generic manufacturers to one per terminally disclaimed group; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.